Pre Solange Peters
MD, PhD
Professeure ordinaire UNIL
Cheffe du Service d'oncologie médicale
Responsable de la Consultation spécialisée des tumeurs thoraciques
Service d'oncologie médicale
Département d'oncologie UNIL CHUV
Intérêts cliniques ou académiques
Spécialisations
Tumeurs thoraciques, cancers pulmonaires et tumeurs pleurales. Les tumeurs thoraciques incluent:
- Cancer bronchique non à petites cellules
- Cancer bronchiques à petites cellules
- Carcinoïdes bronchiques
- Tumeurs thymiques
- Mesotheliomes
- Tumeurs pleurales
- Métastases intrathoraciques
Activités de recherche
Recherche fondamentale qui se focalise principalement sur les nouveaux biomarqueurs et leur validation au sein des procédures, études précliniques et cliniques, et enfin recommandations pour la prise en charge des patient-es au niveau européen.
Pre Peters est également active dans les approches innovatives en termes de traitements multimodaux (radiothérapie, chimiothérapie et chirurgie) et gère l’organisation et la coordination d’essais cliniques, ainsi que les bases de données de l’European Thoracic Oncology Platform (ETOP). Cette large plateforme permet à ce jour d'étudier de multiples approches nouvelles dans le traitement des tumeurs thoraciques dans le monde.
Études cliniques sélectionnées en cours
- Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial. SAKK 16/08
- A randomized phase III trial evaluating the addition of Denosumab to standard first-line anticancer treatment in advanced NSCLC. Survival improvement in Lung cancer induced by Denosumab therapy ETOP/EORTC SPLENDOUR
- A randomized phase II trial of consolidation ipilimumab vs observation in stage I-III ("limited disease") small cell lung cancer after chemoradiotherapy ETOP STIMULI
Formation
- 2019: Professeure ordinaire (UNIL)
- 2016: Professeure associée (UNIL)
- 2006/12: European Society for Medical Oncology (ESMO) examen en oncologie
- 2006/10/12: Certficat de bonnes pratiques pour investigateurs et coordinateurs d'études-Swissmedic niveau 1-3
- 2006: Société Suisse d'oncologie médicale, examen oral
- 2002: PhD
- 1998: Doctorat en médecine
Langues
- Français
- Allemand
- Italien
- Anglais
Age des patients
- Adultes
Publications scientifiques sélectionnées
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML
J Thorac OncolLong-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS
J Thorac OncolLurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer
Dómine Gómez M, Subbiah V, Peters S, Sala MA, Trigo J, Paz-Ares L, Nieto Archilla A, Gomez Garcia J, Alvarez García C, López-Vilariño de Ramos JA, Kahatt Lopez C, Fernandez CM
Expert Rev Anticancer TherImmunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study
Weller M, Le Rhun E, Tsamtsouri L, Dummer R, Guckenberger M, Ribi K, di Giacomo AM, Minuti G, Collazo-Lorduy A, Brandsma D, O'Brien M, Ermis E, Fischer N, Ascierto P, Mandala M, Minniti G, Iranzo P, Roschitzki-Voser H, Ruepp B, Grolimund E, Dafni U, Peters S, Stahel R, ETOP 19-21 USZ-STRIKE collaborators
Lung CancerAdjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
Uprety D, Roden AC, Peters S
J Thorac OncolFirst-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK
J Clin OncolLandscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types
Semaan K, Nawfal R, Nally E, Janjigian YY, Robert C, Peters S, Powles T, Choueiri TK
Lancet OncolPrevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project
Haberecker M, Rüschoff JH, Andriakopoulou C, Gray SG, Nackaerts K, De Perrot M, Brcic L, Nadal E, Tsimpoukis S, Ampollini L, Aerts JG, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, Von Der Thüsen J, Vagenknecht P, Tsourti Z, Kerr KM, Kammler R, Peters S, Baas P, Opitz I, Stahel RA, Curioni-Fontecedro A, ETOP Mesoscape Consortium, TransSCOT Consortium
JCO Precis OncolHyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Hao Y, Gkasti A, Managh AJ, Dagher J, Sifis A, Tiron L, Chriqui LE, Marie DN, De Souza Silva O, Christodoulou M, Peters S, Joyce JA, Krueger T, Gonzalez M, Abdelnour-Berchtold E, Sempoux C, Clerc D, Teixeira-Farinha H, Hübner M, Meylan E, Dyson PJ, Cavin S, Perentes JY
Cancer Immunol ResDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B
J Immunother CancerProceedings of the 1st biannual bridging the gaps in lung cancer conference
Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E
OncologistAntibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, Naidoo J, Koutoukoglou P, Cani M, Lefevre A, Addeo A, Peters S, Remon J
Cancer Treat RevImmunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Wang Y, Safi M, Hirsch FR, Lu S, Peters S, Govindan R, Rosell R, Park K, Zhang JJ
Nat Rev Clin Oncol
Calls to action on lung cancer management and research
Meyer ML, Hirsch FR, Bunn PA, Ujhazy P, Fredrickson D, Berg CD, Carbone DP, Halmos B, Singh H, Borghaei H, Ferris A, Langer C, Dacic S, Mok TS, Peters S, Johnson BE
OncologistIdentifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study
Jolidon V, Eicher M, Peytremann-Bridevaux I, Aebi S, Anchisi S, Bettini A, Chalandon Y, Dietrich PY, Duchosal MA, Dürr D, Peters S, von Moos R, Wicki A, Arditi C
Cancer
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M
Lung CancerDisparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U
Lung Cancer
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, Opitz I, ETOP Mesoscape consortium
Mod PatholA differential process mining analysis of COVID-19 management for cancer patients
Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Ferahta N, Cesbron J, Lofek S, Huber A, Jankovic J, Demicheli R, Bouchaab H, Digklia A, Obeid M, Peters S, Eicher M, Pradervand S, Michielin O
Front Oncol
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM
J Thorac OncolCOVID-19 and Cancer: A Review of the Registry-Based Pandemic Response
Desai A, Mohammed TJ, Duma N, Garassino MC, Hicks LK, Kuderer NM, Lyman GH, Mishra S, Pinato DJ, Rini BI, Peters S, Warner JL, Whisenant JG, Wood WA, Thompson MA
JAMA Oncol
Radiomics Feature Activation Maps as a New Tool for Signature Interpretability
Vuong D, Tanadini-Lang S, Wu Z, Marks R, Unkelbach J, Hillinger S, Eboulet EI, Thierstein S, Peters S, Pless M, Guckenberger M, Bogowicz M
Front OncolTargeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
Burns TF, Borghaei H, Ramalingam SS, Mok TS, Peters S
J Clin Oncol
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S
J Thorac OncolMultiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient
Pillonel V, Dunet V, Hottinger AF, Berthod G, Schiappacasse L, Peters S, Michielin O, Aedo-Lopez V
J Immunother Cancer
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A
J Thorac OncolActivity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC
J Thorac Oncol
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project
Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA, Lungscape Consortium
Lung CancerImmunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer
Rizvi NA, Peters S
N Engl J Med
Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I
Merz L, Zimmermann S, Peters S, Cavassini M, Darling KE
OncologistCareer opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M
ESMO Open
Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities
Wang X, Gronchi F, Bensimon M, Mercier T, Decosterd LA, Wagnières G, Debefve E, Ris HB, Letovanec I, Peters S, Perentes JY
Lasers Surg MedPatients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study
Favre-Bulle T, Baudat D, Darling KE, Mamin R, Peters S, Cavassini M, Hugli O
Swiss Med Wkly
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib
Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J
Lung CancerStrategies for improving outcomes in NSCLC: a look to the future
Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA
Lung Cancer
Therapeutic advances in non-small cell lung cancer
Vallières E, Peters S, Van Houtte P, Dalal P, Lim E
ThoraxImpact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome
Perentes J, Bopp S, Krueger T, Gonzalez M, Jayet PY, Lovis A, Matzinger O, Ruffieux C, Ris HB, Letovanec I, Peters S
Ann Thorac Surg
Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach
Stupp R, Betticher D, Ris HB, Peters S, Pless M
J Clin OncolExtrapleural pneumonectomy with venous confluence resection for stage IVA thymic tumors
Gonzalez M, Krueger T, Perentes JY, Matzinger O, Peters S, Ris HB
Ann Thorac Surg
Solitary choriocarcinoma in the lung
Berthod G, Bouzourene H, Pachinger C, Peters S
J Thorac OncolPhotodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs
Cheng C, Debefve E, Haouala A, Andrejevic-Blant S, Krueger T, Ballini JP, Peters S, Decosterd L, van den Bergh H, Wagnieres G, Perentes JY, Ris HB
Lasers Surg Med
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M
Lancet OncolThalidomide in small cell lung cancer: wrong drug or wrong disease?
Rüegg C, Peters S
J Natl Cancer Inst
Service d'oncologie médicale
Le Service d'oncologie médicale prend en charge les patient-es adultes atteints d'un cancer.
En savoir plus- (ouvre une nouvelle fenêtre)
- Suivant
- Précédent
- (ouvre une nouvelle fenêtre)
- Suivant
- Précédent